{
  "name" : "zero.sci-hub.se_5301_13fec5ad261ec98a1f7e4a7957e18dad_shao2016.pdf",
  "metadata" : {
    "source" : "META",
    "title" : "Janus ``nano-bullets'' for magnetic targeting liver cancer chemotherapy",
    "authors" : [ "Dan Shao", "Jing Li", "Xiao Zheng", "Yue Pan", "Zheng Wang", "Ming Zhang", "Qi-Xian Chen", "Wen-Fei Dong", "Li Chen" ],
    "emails" : [ "wenfeidong@126.com", "chenl@jlu.edu.cn" ],
    "sections" : [ {
      "heading" : null,
      "text" : "lable at ScienceDirect\nContents lists avai\nBiomaterials\njournal homepage: www.elsevier .com/locate/biomateria ls\nJanus “nano-bullets” for magnetic targeting liver cancer chemotherapy\nDan Shao a, b, d, 1, Jing Li a, 1, Xiao Zheng a, Yue Pan a, Zheng Wang a, b, Ming Zhang a, Qi-Xian Chen b, Wen-Fei Dong b, *, Li Chen a, c, **\na Department of Pharmacology, Nanomedicine Engineering Laboratory of Jilin Province, College of Basic Medical Sciences, Jilin University, Changchun 130021, China b CAS Key Laboratory of Bio-Medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, Suzhou 215163, China c School of Nursing, Jilin University, Changchun 130021, China d Department of Biomedical Engineering, Columbia University, New York, NY 10027, USA\na r t i c l e i n f o\nArticle history: Received 9 May 2016 Accepted 17 May 2016 Available online 24 May 2016\nKeywords: Magnetic mesoporous silica Janus Magnetic targeting Liver cancer Chemotherapy Low systemic toxicity\n* Corresponding author. ** Corresponding author. Department of Ph Engineering Laboratory of Jilin Province, College of University, Changchun 130021, China.\nE-mail addresses: wenfeidong@126.com (W.(L. Chen).\n1 These authors contributed equally to this work.\nhttp://dx.doi.org/10.1016/j.biomaterials.2016.05.030 0142-9612/© 2016 Elsevier Ltd. All rights reserved.\na b s t r a c t\nTumor-targeted delivery of anti-cancer drugs with controlled drug release function has been recognized as a promising strategy for pursuit of increased chemotherapeutic efficacy and reduced adverse effects. Development of magnetic nanoparticulates as delivery carriers to accommodate cytotoxic drugs for liver cancer treatment has evoked immense interest with respect to their convenience in biomedical application. Herein, we engineered multifunctional Janus nanocomposites, characterized by a head of magnetic Fe3O4 and a body of mesoporous SiO2 containing doxorubicin (DOX) as “nano-bullets” (M-MSNsDOX). This nanodrug formulation possessed nanosize with controlled aspect-ratio, defined abundance in pore structures, and superior magnetic properties. M-MSN-DOX was determined to induce selective growth inhibition to the cancer cell under magnetic field rather than human normal cells due to its preferable endocytosis by the tumor cells and pH-promoted DOX release in the interior of cancer cells. Ultimately, both subcutaneous and orthotropic liver tumor models in mice have demonstrated that the proposed Janus nano-bullets imposed remarkable suppression of the tumor growth and significantly reduced systematic toxicity. Taken together, this study demonstrates an intriguing targeting strategy for liver cancer treatment based on a novel Janus nano-bullet, aiming for utilization of nanotechnology to obtain safe and efficient treatment of liver cancer.\n© 2016 Elsevier Ltd. All rights reserved."
    }, {
      "heading" : "1. Introduction",
      "text" : "Liver cancer, characterized with formidable mortality and high propensity of recurrence, spurred intensive efforts in development of advanced therapeutic approaches for treatment of this intractable carcinogenesis [1e3]. The ensuing researches pertaining to liver cancer provided implication of the importance of early diagnosis and targeting chemotherapy in circumventing the high mortality of liver cancer [4,5]. Systemic dosage of\narmacology, Nanomedicine Basic Medical Sciences, Jilin\nF. Dong), chenl@jlu.edu.cn\nchemotherapeutic drugs is prescribed as a routine in clinical treatment of advanced liver cancer, nevertheless concomitantly eliciting severe adverse effects due to non-specific cytotoxicity [6,7]. Plausible strategies to address this problem convergewith the thriving development of nanotechnology. The development of nanoscaled drug delivery systems for tumor-targeted delivery and tumor cell-targeted cytotoxicity is particularly emphasized in the scope of cancer treatment [8e10]. In consequence, tumor-targeted delivery or tumor cell-targeted cytotoxicity by virtue of multifunctionalities of drug delivery systems can elicit appreciable drug availability, thus improved therapeutic efficacy to the tumors and reduced non-specific toxicity for vital functional organs [11,12]. In this regard, development of multifunctional inorganic nanoparticles as drug delivery vehicles has become highlighted as a promising modality for treatment of intractable liver cancer.\nRecently, core-shell architectural magnetic mesoporous nanoparticles (M-MNPs) as intriguing drug delivery vehicles for\nencapsulation of chemotherapy drugs or therapeutic nucleic acid materials have attracted ever-growing attention with respect to their unique magnetic-mediated targeting functions, convenience in drug-loading, appreciable adaptability in subsequent biochemical engineering and intrinsic safety profile [13e16]. However, several drawbacks are connected with the core-shell architecture, including considerable interference in magnetic response, and limited presence of mesopore formation constrained their clinical applications [17,18]. These drawbacks encouraged us to further develop sophisticated multifunctional formulations to achieve a breakthrough in theranostics of cancer utilizing the intrinsic properties of the nanomaterials.\nJanus particles, defined by Casagrande and de Gennes after the double-faced Roman mythology god, have emerged as a new division of colloidal structures [19,20]. Janus particles have been obtained originally from polymeride, but recently also from inorganics containing iron, gold, silver, and oxide, metal or semiconductor materials [21e24]. Although Janus particles combine individual components, their fingerprint magnetic, optical and electronic properties are not often interfered or altered, in contrast with other isotopic nanoparticles [25,26]. Therefore, anisotropic particles with tunable composition and morphology exhibit multiple functionalities that have been proven useful for cell targeting, non-invasive imaging, and/or therapeutic applications [27,28]. These characteristics of the Janus nanoparticles render them truly “multifunctional entities”. A variety of fabrication methods have been reported to synthesize magnetic Janus nanoparticles for applications such as surfactants, magnetic-fluorescence imaging, catalysis, and drug delivery [29e31]. However, only a few studies explored the potential of Janus nanoparticles for multifunctional drug delivery applications simultaneously achieving magnetic targeting and controlled drug release in cancer therapy.\nTo develop effective and safe approaches for liver cancer chemotherapy, we engineered multifunctional Janus nanocomposites combining a magnetic Fe3O4 head with a mesoporous SiO2 body. Such Janus nano-bullets not only have a uniform size with designable aspect-ratio and well-defined pore structures, but also possess superior magnetic properties. The strong magnetism contributes to tumor targeting mediated by the enhanced permeability and retention (EPR) effect. The anti-tumor agent doxorubicin (DOX) was preloaded into the silica body via pH-sensitive carboxyl groups resulting in tumor microenvironment-responsive release of drugs. Consequently, one can anticipate enhanced efficacy of chemotherapy and reduced adverse effects due tomagnetic-guided accumulation in the tumor site and the “zero” release of DOX in neutral blood circulation and normal tissue.\nIn this work, we engineered M-MSNs-DOX multifunctional nanoparticles integrating Janus Fe3O4 magnetic head with DOXloaded mesoporous SiO2 body as “nano-bullets”, and nano-scaled characteristics, magnet field-enhanced endocytosis, pH-controlled drug release were evaluated for a series of cancer cells and normal cells. Efficacy for selective cytotoxicity to the cancerous cells was demonstrated in orthotropic and subcutaneous transplanted liver tumor model in nude mice, which concomitantly resulted in significant reduction in systemic toxicity (Scheme 1). Hence, it can be envisioned that the proposed Janus nano-bullet is a tempting platform for developing versatile functionalities to pursue specificity to liver cancer tumor therapy."
    }, {
      "heading" : "2. Materials and methods",
      "text" : ""
    }, {
      "heading" : "2.1. Reagents and materials",
      "text" : "Polyacrylic acid (PAA, 8 mmol, Mw ¼ 1800), iron (III) chloride anhydrous (FeCl3), diethylene glycol (DEG), cetyltrimethyl\nammonium bromide (CTAB), tetraethyl orthosilicate(TEOS, 98%), 3- Aminopropyltriethoxysilane(APS), fluorescein isothiocyanate (FITC), Sulforhodamine B(SRB), NaN3, amiloride, simvastatin, mycostatin, and chlorpromazine were purchased from SigmaAldrich. Sodium hydroxide (NaOH), ammonium hydroxide (NH4OH, 28%), ammonium nitrate(NH4NO3), anhydrous ethanol, sucrose, potassium ferrocyanide, hydrochloric acid and succinic anhydride were purchased from Beijing Chemical Reagent Co.(Beijing China). Dulbecco's modified Eagle medium-high glucose (DMEM-HG), RPMI-1640 medium and fetal bovine serum (FBS) were obtained from GIBCO. Penicillin and streptomycin were from Beyotime Institute of Biotechnology Co.(Jiangsu, China). Diagnostic kits for aspartate aminotransferase (AST), alanine aminotransferase (ALT), blood urea nitrogen (BUN), creatinine (CRE), and phosphocreatine kinase (CK) were purchased from Nanjing Jiancheng Bioengineering Institute. All reagents were commercially available products of analytical grade purity and were used without further purification."
    }, {
      "heading" : "2.2. Synthesis of M-MSNs",
      "text" : "Uniform sized M-MSNs were synthesized using the previously reported method [29]. The Fe3O4 magnetic spheres were produced using a high temperature hydrolysis reaction [32]. With TEOS as a silica source, cetyltrimethyl ammonium bromide (CTAB) as a template and Fe3O4 NPs as a substrate, a mesoporous silica rod could be formed on Fe3O4 sphere. CTAB (50 mg) was dissolved in 10 mL ultrapure water under ultrasonic treatment. 1 mL Fe3O4 (8.6 mg mL 1) solution was added to the CTAB solution, and then ultrasonic treatment was applied for 30 min. The mixture was mechanically stirred at 40 C in a water bath and 0.5 mL NH4OH was injected into the solution, followed by a certain amount of TEOS. The aspect ratio (3:1) of the rod-like NPs could be facilely controlled by the molar ratio of [TEOS 10 7]/[Fe3O4] (5:1). After 30 min, magnetic-mesoporous rod-like M-MSNs were obtained and were washed with ethanol three times quickly. To extract CTAB from the M-MSNs, as-synthesized product was dispersed in the ethanol solution of NH4NO3 (60 mL, 10 mg mL 1). The mixture was refluxed for 6 h and washed with ethanol three times.\n2.3. Surface modification of M-MSNs\nM-MSNswere functionalizedwitheNH2 using the post-grafting method [33]. The eCOOH functionalization of M-MSNs was carried out in N,N-dimethylformamide (DMF). 10 mg of M-MSNs-NH2 was added in the DMF solution of succinic anhydride (50 mL, 2 wt%). The mixture was stirred for 24 h at room temperature. After that, the product was washed with ethanol three times and dried under vacuum. The synthesized sample was denoted as M-MSNs-COOH."
    }, {
      "heading" : "2.4. Synthesis of M-MSNs-PEG",
      "text" : "3 mL of EDC aqueous solution (2.0 mg mL 1) was added to the 5 mL of M-MSNs-COOH suspension (1.0 mg mL 1), and the mixture was sonicated for another 30 min. After that, 15.0 mg of 8-armpolyethylene glycol-amine was added to the above suspension, and allowed to react overnight. The reaction is terminated by adding mercaptoethanol (4 mL). The solution was centrifuged and washed with water to remove the unreacted PEG. The final product is MMSNs-PEG."
    }, {
      "heading" : "2.5. Characterization",
      "text" : "The size and morphology of as-made nanoparticles were characterized by scanning electron microscopy (SEM, FEI quanta 200F),\nScheme 1. Schematic illustration of the synthetic procedure for the Janus M-MSNs-DOX nano-bullet and application for pH-promoted drug release after magnetic-enhanced endocytosis in cancer cells, as well as magnet targeting liver cancer chemotherapy in vivo.\ntransmission electron microscopy (TEM) images were taken with a Hitachi H-8100IV Transmission Electron Microscope operated at 200 kV. Magnetic measurements were carried out using a TDM-B vibrating sample magnetometer (VSM) at 300 K. Z-potential measurements were performed using a Zeta sizer NanoZS (Malvern Instruments, USA). The specific surface area was determined by the Brunauer-Emmett-Teller (BET) method and the pore size distributions were calculated by the Barrett-Joyner-Halenda (BJH) method. The UVeVis adsorption spectral values were measured on a U-3310 spectrophotometer (Hitachi)."
    }, {
      "heading" : "2.6. Loading and release of DOX",
      "text" : "5 mg of M-MSNs-PEG dispersed in 5 mL of doxorubicine (DOX) solution in PBS (0.5 mg mL 1). After stirring overnight, DOX-loaded NPs (M-MSNs-DOX) were collected and washed with PBS 3 times. M-MSNs-DOX was finally re-dispersed in PBS with a concentration of 1 mg mL 1. The amount of DOX adsorbed was analyzed with UVevis at the wavelength of 480 nm. The supernatant was collected for the calculation of the loading efficiency and drugloading content using the Equations (1) and (2), respectively: (1) Loading efficiency(%)¼Mass of drug in NPs/Initial mass of drug. (2) Drug-loading content (%) ¼ Mass of drug in NPs/Mass of drug loaded NPs.\nTo study the release behavior, 5 mg of DOX-loaded M-MSNs were encapsulated into a dialysis bag (molecular weight cut off 5000) and put into 10 ml of PBS solutions under different pH values (pH ¼ 7.4, 5.5). Then, the releasing process was performed in a shaking table at 37 C. At the designed intervals, the amount of released drug was monitored by UVevis adsorption spectra."
    }, {
      "heading" : "2.7. Cell culture and SRB assay for in vitro anti-cancer activity",
      "text" : "Briefly, human hepatocarcinoma cell HepG2, SMMC-7721, hepatic embryo cells HL-7702, human ovarian cancer cells SKOV-3, human cervical cancer cells Hela, human breast cancer cells MCF7 and human lung carcinoma cells A549 were maintained at 37 C under 5% CO2 in RPMI-1640 medium supplemented with 10% (v/v) heat-inactivated fetal bovine serum, penicillin (100 U mL 1), and streptomycin(100 mg/ml). Human hepatocarcinoma cells Hep3B, Bel-7402, Bel-7404, myocardium cell lines H9C2 and human umbilical vein endothelial cells, HUVEC were maintained at 37 C under 5% CO2 in Dulbecco's modified Eagle's medium-high glucose (DMEM-HG) medium supplemented with 10% (v/v) heatinactivated fetal bovine serum, penicillin (100 U/ml), and streptomycin(100 mg mL 1).\nThe sulforhodamine B (SRB) assay is routinely used for cytotoxicity determination, based on the measurement of live cell protein content. Human hepatocarcinoma cell HepG2, SMMC-7721, Hep3B, Bel-7402 and Bel-7404, hepatic embryo cells HL-7702, human ovarian cancer cells SKOV-3, human cervical cancer cells Hela, human breast cancer cells MCF-7 and human lung carcinoma cells A549, myocardium cell lines H9C2 and human umbilical vein endothelial cells HUVEC were used in this study. In brief, cells were seeded in 96 well plates at a density of 5 103 cells per well overnight, and treated with the indicated different concentrations of M-MSNs-PEG (1.5625, 3.125, 6.25, 12.5, 25, 50 mg mL 1) or MMSNs-DOX (equally to DOX concentration 0.3125, 0.625, 1.25, 2.5, 5 mg mL 1) with or without magnetic fields for 24 or 48 h, respectively. The small NdFeB permanent magnets (5 mm$3 mm cylinder, surface magnetic field of 0.2T) were placed under of the\nwell of 96-well plates during the incubation of about 0.5 h. The optical density (OD) at wavelength of 570 nm was measured and the ratio of cell viability to control group was calculated from the SRB data.\n2.8. Identification of the cellular uptake and their pathways of MMSNs-PEG\nTo determine the M-MSNs-PEG uptake, 5 104 cells per well were cultured in 24-well plates and incubated with FITC-labeled NPs at concentrations of 12.5 mg mL 1. After 3 h, the cells were washed twice again with chilled PBS and treated with 50 nM Lyso Traker Red DND-99 (Invitrogen) for another 1 h, then cells were washed twice and the nuclei were stained with Hoechst 33258 (5 mg mL 1) for 5 min. Then the cells were washed twice with PBS. The fluorescence in cells was detected under the confocal laser scanning microscopy (CLSM) (Olympus FV1000 Japan) equipped with multi-line argon LASER, 405, 488 and 543 nm, and 30 mW Laserclass 3D laser.\nWe further quantitated the uptake dynamics of different shaped M-MSNs-PEG by fluorescence-activated cell sorting, HepG2 or HL7702 cells were seeded in 6-well plates at a seeding density of 5 104 cells per well. After 24 h, FITC-labeled M-MSNsPEG(12.5 mg mL 1) were co-cultured with cells for 3 or 24 h. Afterwards, the supernatant solution was removed, and cells were washed twice with chilled PBS to remove any extracellular NPs. Then, the cells were trypsinized and resuspended in chilled PBS to yield a concentration of 1 106 cells/mL. The as-prepared cells were analyzed by flow cytometry (Becton Dickinson Biosciences, Drive Franklin Lakes, U.S.) for collection of fluorescence intensity at 488 nm.\nFinally, the cellular uptake mechanisms of M-MSNs-PEG were performed by blocking uptake pathway with different treatment inhibitors of endocytosis. The cellular uptakemechanisms of theMMSNs-PEG were identified by blocking the uptake pathway with different treatments. HepG2 and HL-7702 cells were pre-incubated with different inhibitors for 60 min at 37 C. For ATP depletion, the cells were pre-incubated with NaN3 (3.0 mg mL 1). For hindering the clathrin-mediated pathway, the cells were pre-incubated with chlorpromazine (20 mg mL 1) and sucrose (500 mM). To block the caveolae/lipid rafts pathway, the cells were pre-treated with simvastatin (10 mgmL 1). To block the caveolae-mediated pathway, the cells were pre-treated with mycostatin (5 mg mL 1). To hinder the macropinocytosis pathway, the cells were pre-treated with amiloride (10 mg mL 1). To block energy-dependent endocytosis, the cells were incubated at both 37 C and 4 C, then the inhibitorcontaining culture media was discarded, and FITC-labeled MMSNs-PEG(12.5 mg mL 1) were co-cultured with cells for another 3 h. The cells were treated as described before via performing flow cytometry analysis for collection of fluorescence intensity at 488 nm."
    }, {
      "heading" : "2.9. Bio-TEM observations for HepG2 cells",
      "text" : "The HepG2 cells were incubated with 12.5 mg mL 1 of M-MSNsPEG for 3 h. Then, the cells were washed twice with cold PBS and detached by incubationwith 0.25% trypsin. The cell suspensionwas centrifuged at 2000 r$min 1 for 5 min. After removing supernatant, the cells were fixed by glutaraldehyde at room temperature. The samples were rinsed with PBS and dehydrated through a graded ethanol series, then transparentized with propylene oxide. The samples were then embedded in EPOM812 and polymerized in the oven at 37 C for 12 h, 45 C for 12 h and 60 C for 48 h. Ultrathin sections of approximately 70 nm thick were cut with a diamond knife on a Leica UC6 ultramicrotome and transferred to the copper\ngrid. The images were viewed on JEM-1230 electron Microscopy."
    }, {
      "heading" : "2.10. Prussian blue stain",
      "text" : "5 103 HepG2 or HL-7702 cells per well were seeded in 96 well plates and incubated with M-MSNs-PEG at concentrations of 3.125, 6.25, 12.5, 25, 50 mg mL 1 for different incubation time(3, 6, 12, 24 h). The effect of magnetic fields on cell uptake of M-MSNs-PEG was evaluated as follows. 5 103 HepG2 or HL-7702 cells per well were seeded in 96 well plates and incubated with M-MSNs-PEG at concentrations of 3.125, 6.25, 12.5, 25, 50 mg mL 1, for different incubation time(3, 6, 12, 24 h). The small NdFeB permanent magnets (12 mm$3 mm cylinder, surface magnetic field of 0.2 T) were placed under of the well of 24-well plates during the incubation of about 0.5 h, then all of magnets were removed and cells were incubated with for another 2.5, 5.5, 11.5 and 23.5 h in order to match the previous experiments. Following this, the cells were washed with PBS and fixed with 4% paraformaldehyde. Staining was performed by adding freshly prepared working solution consisting of 5% potassium ferrocyanide and 5% hydrochloric acid. Finally, cells were washed with PBS and the photo of cells were taken by biological microscope (Olympus CX21FSEC Japan).\n2.11. Observation and identification of intracellular release of DOX\nTo determine the Intracellular release of DOX, 5 104 HepG2 cells per well were cultured in 24-well plates and incubated with free DOX or DOX-loaded M-MSNs(12.5 mg mL 1) at the same DOX concentrations(2.5 mg mL 1) for different incubation time(3, 12 and 24 h), the experiments were also performed when incubated for 2 h, the media was replaced with fresh medium to incubate for another 2, 11 and 23 h in order to match the previous experiments. After the medium was removed, cells were washed twice again with chilled PBS and the nuclei were stained with Hoechst 33258 (5 mg mL 1) for 5 min. Then the cells were washed twice with PBS. The blue emitting fluorescence in cells was detected under the confocal laser scanning microscopy (CLSM) (Olympus FV1000 Japan) equipped with multi-line argon LASER, 405, 488 nm, and 30 mW Laserclass 3D laser.\nThe effect of magnetic fields on intracellular release of DOX was evaluated as follows. 5 104 HepG2 cells per well were cultured in 24-well plates and incubated with free DOX or DOX-loaded NPs (12.5 mg mL 1) at the same DOX concentrations (2.5 mg mL 1). The small NdFeB permanent magnets (12 mm$3 mm cylinder, surface magnetic field of 0.2 T) were placed under of the well of 24-well plates during the incubation of about 0.5 h, then all of magnets were removed and cells were incubated with for another 2.5, 11.5 and 23.5 h in order to match the previous experiments. For DOX retention study, the small NdFeB permanent magnets (12mm$3mm cylinder, surface magnetic field of 0.2 T) were placed under of the well of 24-well plates during the incubation of about 0.5 h, then the cells were incubated for another 1.5 h, themediawas replaced with fresh medium to incubate for another 1, 10 and 22 h in order to match the previous experiments. After the mediumwas removed, cells were washed twice again with chilled PBS and the nuclei were stained with Hoechst 33258 (5 mg mL 1) for 5 min. Then the cells were washed twice with PBS. The fluorescence in cells was detected under the confocal laser scanning microscopy (CLSM) (Olympus FV1000 Japan) equipped with multi-line argon LASER, 405, 488 nm, and 30 mW Laserclass 3D laser.\nFor quantitative study using flow cytometry, cells were seeded onto 6-well plates at a density of 1 105 cells per well, incubated for 24 h, and treated with free DOX, M-MSNs-DOX, M-MSNs-DOX with magnetic field at a concentration of 12.5 mg mL 1 for 3 and 24 h. Cells without any treatment were used as the control. The\ncells were thenwashedwith PBS and harvested. The cellular uptake of DOX was measured by flow cytometry analysis for collection of fluorescence intensity at 488 nm."
    }, {
      "heading" : "2.12. Orthotopic liver tumor model in ICR mice",
      "text" : "All animal experiment protocols were approved by the Ethics Committee for the Use of Experimental Animals of Jilin University. The H22 liver tumor model in situ was developed to further evaluate antitumor activity of M-MSNs-DOX. Briefly, the ICR mice were anaesthetized by chloral hydrate (10%) and the abdomens below the sternum were carefully cut open. The left hepatic lobe was gently extruded, and then slowly inserted about 1 mm3 H22 tumor tissue from H22 tumor-bearing model as above-mentioned [35]. The abdomens were carefully closed, and then the H22 liver tumor model in situ was established. After 3 days post-surgery, the mice bearing H22 liver tumors in situ were randomly separated into 5 groups (n ¼ 3) and treated with saline, DOX (1 mg kg 1), M-MSNs (5 mg kg 1), M-MSNs-PEG (5 mg kg 1), M-MSNs-DOX (5 mg kg 1) by tail vein injection every 3 days. The small NdFeB permanent magnets (15 mm$5 mm cylinder, surface magnetic field of 0.5 T) was placed on the skin over the liver site for the mice during injection and was maintained for 0.5 h post-injection. The injections were repeated four times over a 16-day treatment period. Then mice were sacrificed after treatment, the tumors from every group were harvested and measured. The fresh tumor tissues were fixed in 10% formalin and then embedded into paraffin, 4 mm tissue sections were made and stained with hematoxylin-eosin (H&E) and TUNEL assay. TUNEL (terminal deoxynucleotidyl transferase-mediated nick-end-labeling) assay detected the apoptotic cells in tumor slice (ApopTag Peroxidase In Situ Apoptosis Detection Kit, Chemicon-Millipore Company, Billerica, MA) according to manufacturer's recommended procedure. Cells that stained positive were counted at 400 magnification in at least 5 different fields."
    }, {
      "heading" : "2.13. Subcutaneous transplanted tumor model and systemic safety evaluation in nude mice",
      "text" : "The mice HepG2 xenograft model was replicated as abovementioned [9]. When tumor volume reached 60e100 mm3, mice were randomized into 5 groups (n ¼ 6) and treated with saline, DOX (1 mg kg 1), M-MSNs (5 mg kg 1), M-MSNs-PEG (5 mg kg 1), M-MSNs-DOX (5 mg kg 1) exposed to a magnetic field 0.5 h, by tail vein injection every 3 days. The small NdFeB permanent magnets (15 mm$5 mm cylinder, surface magnetic field of 0.5 T) was placed on the skin over the tumor site for the mice during injection and was maintained for 0.5 h post-injection. The injections were repeated six times over a 25-day treatment period. The body weights and tumor sizes were accurately recorded once three days and the tumor volume was calculated according to the formula: length Width2 0.52. The mice were sacrificed 26 days after implantation tumor cells. All tumors and major organs (heart, liver, spleen, lung, and kidney) were removed and weighted. Serum was collected after centrifuging the whole blood at 3000 rpm for 15 min. The biochemical parameters, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN), creatinine (CRE), and phosphocreatine kinase (CK) were assayed. In addition, the main tissues including tumors, livers, kidneys, spleens, lungs, and hearts were fixed in 10% formalin and then embedded into paraffin. 4 mm tissue sections were made and stained with hematoxylin-eosin (H&E). The safety evaluations in tissue slices were conducted by an experienced veterinary pathologist."
    }, {
      "heading" : "2.14. In vivo biodistribution of DOX-loaded NPs",
      "text" : "To investigate DOX-loaded M-MSNs in orthotopic liver tumor model, 0.2 ml of DOX (1 mg Kg 1) and M-MSNs-DOX (DOX: 5 mg Kg 1, M-MSNs-PEG: 5 mg Kg 1) were intravenous injected into mice bearing H22 liver tumors in situ (n ¼ 3). The small NdFeB\npermanent magnets (15 mm$5 mm cylinder, surface magnetic field of 0.5 T) was placed on the skin over the liver site for the mice during injection and was maintained for 0.5 h post-injection. After injection for 3 h, all the mice were sacrificed to collect heart, liver, spleen, lung, kidney and tumor, then the collected tissues were made into frozen sections. The nuclei were stained using Hoechst 33258 dye (5 mg/ml) for 5 min and imaged under the confocal laser scanning microscopy (CLSM, Olympus FV1000 Japan) equipped with multi-line argon LASER, 488 nm, and 30 mW Laserclass 3D laser.\nTo investigate DOX-loaded M-MSNs in subcutaneous\ntransplanted tumor model, After 26 days treatment, all the mice were sacrificed and tumors and major organs (heart, liver, spleen, lung, and kidney) were removed and 4 mm tissue sections were made. Prussian blue staining was used to confirm the presence of M-MSNs in the tumor and normal tissue sections using our establishedmethod. Briefly, sections were then incubated at 37 C for 4 h with 10% (g mL 1) of K4Fe(CN)6 in 5%(V/V) HCL (freshly made). Sections were washed with PBS 3 times and stained with Fast Red for 30 min at room temperature."
    }, {
      "heading" : "2.15. Statistical analysis",
      "text" : "Datawere expressed asmean ± SD. The statistical significance of the data was compared by Student's test. Analysis of variance (ANOVA) was used to analyze the differences among the different groups."
    }, {
      "heading" : "3. Results and discussion",
      "text" : ""
    }, {
      "heading" : "3.1. Synthesis and characterization of M-MSNs-PEG",
      "text" : "TheM-MSNs-PEG were synthesized by the following procedure. Firstly, water-dispersible Fe3O4 cores with a diameter of approximately 100 nm were prepared via a high temperature hydrolysis reaction using polyacrylic acid as a stabilizer [32]. Next, a modified sol-gel process was developed, themesoporous silicawas coated on the surface of Fe3O4 via a self-assembly process using CTAB as a template and tetraethyl orthosilicate (TEOS) as a silica source in aqueous ammonia. Aiming for pH-responsive DOX release, MMSNs were functionalized with eCOOH using the post-grafting method [33]. Ultimately, biocompatible PEG was attempted to tether onto the surface of the formulated M-MSNs aiming to acquire improved stealth behavior in the blood circulation The morphology of the formulated structure was characterized by transmission electron microscopicy (TEM) and scanning transmission electronmicroscopicy (SEM). As presented in Fig.1AeC and Fig. S1 B and C, uniform anisotropic nanoscaled structures were observed, characterized with a round-shaped Fe3O4 head attached (approximate 100 nm) with extended shaft (approximately 200 nm in length). The M-MSNs was designed to possess good magnetic response with a saturation magnetization at 61 emu g 1, hence once exposed to an external magnetic field they could be rapidly attracted by the magnet (Fig. 1D). It is worthwhile to note that the\nsaturation magnetization of Janus M-MSNs was much higher than our previously reported core-shell M-MSNs (41 emu g 1) [34]. Moreover, N2 adsorption/desorption isotherms (Fig. 1E) demonstrated that M-MSNs have well-defined mesopores of approximately 2.8 nm, the Brunauer-Emmett-Teller (BET) surface area and the total pore volume were as high as 615.3 m2 g 1 and 0.43 cm3 g 1, respectively, which is higher than 423.6 m2 g 1 and 0.3 cm3 g 1 of core-shell M-MSNs [34]. Furthermore, Fig. S1A shows Zeta potentials of 10.7, 14.2, þ5.19, 30.1, 9.62, and þ6.89 mV, for M-MSN, M-MSN(CTAB free), M-MSN-NH2, MMSN-COOH, M-MSN-PEG and M-MSN-DOX, respectively. While being well dispersed in PBS solution or DMEM cell culture medium, M-MSNs-PEG exposure to an external magnetic field could be rapidly attracted by the magnet filed (Fig. S1 D and E). Physical stability of these Janus nanoparticles, following incubation for 1 week in PBS solution or DMEM media was confirmed (Fig. S1 F). Collectively, these results confirm that M-MSNs-DOX is successfully synthesized with good magnetic properties, uniformity and dispersity."
    }, {
      "heading" : "3.2. Cytotoxicity and endocytosis of M-MSNs-PEG in vitro",
      "text" : "To assess the cytotoxicity of PEGylated M-MSNs, the Sulforhodamine B (SRB) assay was conducted with varying M-MSNsPEG concentration from 0 to 50 mg mL 1 in a series of liver cancer cell lines, including HepG2, HepG3B, Huh-7, SMMC-7721, Bel-7402, Bel-7404, H22, Hepa and breast cancer cell line MCF-7, lung cancer cell line A549, ovary cancer cell line SKOV-3, cervical cancer cell line Hela, as well as the normal cells lines, such as HL-7702, H9C2, HUVEC and 3T3-L1, Fig. S2 shows that no or negligible cytotoxicity was observed neither in tumor cell lines nor in normal cell lines, indicating that M-MSNs-PEG as nanocarrier is non-toxic, when the concentration is less than 50 mg mL 1, Consequently, we\nsubsequently carried out experiments at the dosage range from 12.5 mg mL 1 to 50 mg mL 1.\nTo explore the potential utility of the proposed formulation as drug delivery vehicle, it is critical to determine its cellular uptake activity, particularly, the cellular uptake efficiency to tumor cells as compared to healthy cells [35]. Apparently, preferable internalization into the tumor cells over healthy cells would elicit selective therapeutic efficacy to the tumors and reduce the adverse toxicity [36]. In this work, we detected endocytosis behavior with human hepatocelluar carcinoma cell lines (HepG2) and human hepatic embryo cell lines (HL-7702) by confocal microscopy (Fig. 2A). The two cell lines were incubated with 12.5 mg mL 1 green FITC-labeled M-MSNs-PEG for 3 h, and Hoechst 33258 for nuclei staining was followed by Lyso Tracker Red DND-99 for lysosome staining. Yellow signal, overlapping with the red lysosome and green M-MSNs-PEG nanoparticles, suggest that most M-MSNs-PEG have entered the lysosomes while some are in the cytoplasm. No fluorescence signals of M-MSNs-PEG are located in the nuclei, indicating that M-MSNs-PEG could not pass through\nthe nuclear membrane. It should be noted that M-MSNs-PEG accumulation in HepG2 cells was higher than that in HL7702 cells, indicating that M-MSNs-PEG induces a higher cellular uptake in tumor cells compared to normal cells.\nTo elucidate the cellular endocytosis pattern and themechanism of M-MSNs-PEG, Bio-TEM images and different endocytosis inhibitors were employed. Bio-TEM images of HepG2 cells (Fig. 2B) show a large number of M-MSNs-PEG in the cytoplasm, also keeping their rodmorphology. Fig. 2C visualizes the uptake process through the cell membrane; M-MSNs-PEG are enclosed by membrane pseudopod to form membrane invagination, then internalized and processed in endosomes or lysosomes, eventually released into the cytoplasm. Moreover, to study the possible cellular uptake pathway of M-MSNs-PEG, different endocytosis inhibitors including chloroquine (increasing endosomal pH), NaN3 (ATP depletion), low temperature (blocking energy-dependent endocytosis), amiloride (macropino-cytosis inhibitor), chlorpromazine (CPZ) and sucrose (clathrin-mediated pathway blocker), mycostatin and simvastatin (caveolae-mediated pathway blocker), were used\n[37]. The results show that the endocytosis of M-MSNs-PEG is significantly suppressed by NaN3, low temperature and CPZ, indicating that nanoparticle M-MSNs-PEG uptake has the characteristics of energy dependent clathrin involvement (Fig. 2D).\n3.3. Magnet field-enhanced endocytosis of M-MSNs-PEG\nNanoparticulates were verified to be capable of passive accumulation into the tumors through the enhanced permeability and retention (EPR) effect [38,39]. Recent studies claimed that this passive tumor accumulation could be facilitated by an external stimulus, such as magnetic field (MF), light, and ultra-sound [40,41]. As one intriguing approach, magnetic-mediated targeting\nvia an external magnetic field on the tumor site was able to direct transportation of magnetic nanoparticles to the tumor sites [42,43]. To validate the utility of magnetic fields in promoting cell uptake of M-MSNs-PEG nanoparticles, the cellular uptake M-MSNs-PEG in absence and presence of a magnetic field was evaluated, where Prussian blue was used to selectively stain Fe3O4 for quantification of cellular uptake efficacy. As shown in Fig. 3A; Fig. S3 and S4, the magnetic field markedly increases the amount of M-MSNs (50 mg mL 1) either in HepG2 cells or HL-7721 cells in a dose- and time-dependent manner. Higher fluorescence intensity was detected in HepG2 and HL-7702 cells after 3 or 24 h of exposure with FITC-labeled M-MSNs-PEG (12.5 mg mL 1) in the magnetic field treated group than that of the non-magnetic field untreated\ngroup (Fig. 3B). We also found that the endocytosis of M-MSNs-PEG in HepG2 cells was more than that in HL-7702 cells with or without magnetic field, which is in line with confocal microscopy images in Fig. 2A. These indicate that M-MSNs-PEG possess excellent magnetic properties, which facilitate directed transportation of anticancer drug and selectively enhancing endocytosis of the tumor cell.\nAlthough we have demonstrated that a magnetic field can enhance endocytosis of M-MSNs-PEG, it is necessary to investigate the cytotoxicity of M-MSNs-PEG in the presence of magnetic external stimuli. Thus, we further evaluate the cytotoxicity of the M-MSNs-PEG under magnetic field. As Fig. 3C-H and Fig. S5 depict, M-MSNs-PEG show no increased cytotoxicity compared with the absence of magnetic field on the various cancer cells (HepG2, A549, SKOV-3) and normal cells (HL-7702, HUVEC, H9C2). In conclusion, magnetic field-enhanced endocytosis of M-MSNs-PEG neither influenced cancer cells nor normal cells."
    }, {
      "heading" : "3.4. Magnetically-enhanced DOX accumulation in liver cancer cells",
      "text" : "To explore the payload capability of M-MSNs-PEG as anticancer drug delivery vehicles, a typical cytotoxic chemotherapy drug, doxorubicin (designated as DOX), was chosen as a model drug because DOX and its analogues are not only widely used in chemotherapy, but also it has auto-emission red fluorescence and has achieved appreciable clinical effects. But its application in clinic is restricted due to its severe non-specific side-effects such as dose-\ndependent cardiotoxicity [44,45]. The loading efficiency of DOX on M-MSNs was around 60%, and the drug-loading content was 20% as determined by UVevis spectrophotometry, which is much higher than the 49% of loading efficiency in core-shell M-MSNs [34]. We also monitored and compared the fluorescence change of DOX in M-MSNs (Fig. 4 A), it is observed that the fluorescence of DOX is quenched when the compound is adsorbed onto pore of our Janus NPs as a result of electronic energy transfer, indicating that a majority of DOX were loading in pores rather than NPs surface. Then the drug-releasing behavior of M-MSNs-DOX is quite different under pH 5.5 and 7.4 phosphate buffers (Fig. 4B). The cumulative content of releasing DOX is less than 5% at pH 7.4 in 24 h, while as much as 50% of DOX is released at pH 5.5 in 24 h, indicating that DOX can be released by the protonate and dissociate triggered in acidic environments. It is worth noting that this property of pHsensitive drug release is favorable for cancer therapy, since the microenvironments of extracellular tumor tissue, as well as intracellular lysosomes and endosomes are acidic, facilitating active drug release from the M-MSNs-based DOX delivery vehicles.\nTo further confirm whether M-MSNs-DOX is released more in cancer cells than in normal cells, the red fluorescence of DOX was determined in HepG2 cells and HL-7702 cells after a-24 h incubation, fluorescence intensity detected by flow cytometry is in line with the free DOX concentration, and higher fluorescence intensity is detected in the liver cancer cell HepG2 than in hepatic embryo HL-7702 cells (Fig. S6). More importantly, HepG2 cells incubated with M-MSNs-DOX in the presence of the magnetic field, showed\nremarkably enhanced DOX accumulation after a-24 h incubation, which is consistent with CLSM images visualizing intracellular DOX release from 3 to 24 h (Fig. 4C and Fig. S7-9). Given that the main reason for tumor chemotherapy resistance to DOX is the rapid pump-out by p-gp, we compared the efflux of M-MSNs-DOX in different groups. At 2 h post drug treatment, the cells were washed and allowed to efflux for another 10 or 22 h. Confocal microscopy images show that DOX was accumulated more for the M-MSNsDOX group than for the DOX group, and the magnetic field also increased DOX retention (Figs. S10 and S11). Taken together, these results indicate that M-MSNs-DOX exhibits enhanced endocytosis, then releases drug pH-sensitively, overcoming the pump efflux, thus expanding the chemotherapeutic efficacy with magnetic responsiveness."
    }, {
      "heading" : "3.5. Magnetically-improved antitumor effect of M-MSNs-DOX in vitro",
      "text" : "To assess the cytotoxicity of M-MSNs-DOX, the SRB assay was conducted with different tumor cell lines and normal cells incubated with DOX and M-MSNs-DOX containing the same amount of DOX, under the absence or presence of magnetic external stimuli for 24 h or 48 h incubation (Fig. 5 and Fig. S12). As shown in Fig. 5 A\nand D, killing effects of M-MSNs-DOX in HepG2 cells exhibit a dose and time-dependence, and an external magnetic field can significantly enhance the anti-tumor effect. In contrast, HL-7702 cells appear more vulnerable to free DOX comparing HepG2 cells, while M-MSNs-DOX displays significantly reduced damage to HL7702 cells whether or not under magnetic field. This phenomenon was demonstrated with tumor A549 cells and SKOV-3 cells (Fig. 5 B and C), as well as the other normal H9C2 cells and HUVEC cells (Fig. 5 E and F). These results indicate that the selective anticancer pattern of M-MSNs-DOX originates from the higher endocytosis capacity and pH-sensitive drug release in the tumor cell. Moreover, an external magnetic field further increases the target selectivity and efficacy of M-MSNs-DOX in liver cancer therapy."
    }, {
      "heading" : "3.6. Magnetically targeted chemotherapy of M-MSNs-DOX in vivo",
      "text" : "We utilized two mice tumor models to evaluate the antitumor effect of M-MSNs-DOX in the presence and absence of a magnetic field. Firstly, an orthotropic liver tumor model was duplicated by transplanting the volume of 1 mm3 H22 tumor tissue into the liver of ICR mice. Three days later, DOX (1 mg kg 1) and M-MSNs-DOX (5 mg kg 1, equal to containing 1 mg kg 1 DOX) were administered through tail vein injection for 4 times (Fig. 6A), and after 16 days\ntreatment, DOX or M-MSNs-DOX could effectively inhibit in situ liver tumor growth, but M-MSNs-DOX under external magnetic field displayed a significant tumor volume and weight reduction compared to other group (Fig. 6B and C). Additionally, the KaplanMeier survival plot (Fig. 6D) shows that M-MSNs-DOX with magnetic field survival rate is 62.5% comparing to that of 50% in the MMSNs-DOX group, as well as 37.5% in the DOX group. TUNEL assays in liver transplanted tumor slice revealed magnetic targeted MMSNs-DOX treatment resulting in highest apoptosis rate in tumors compared to the control, DOX andM-MSNs-DOX group (Fig. 6 E and F). These results illustrate thatM-MSNs-DOX effectively inhibits the growth of H22 liver tumors in situ, magnetic field enhanced efficacy and selectivity in tumor inhibition.\nTo elucidate the mechanisms of tumor selective of M-MSNsDOX, the intra-tissue distributions of DOX were detected by fluorescence imaging of frozen tissue section. 24 h after single intravenous injection M-MSNs-DOX (5 mg kg 1), confocal microscopy images of tissue sections were taken from heart, spleen, kidney, lung, liver, and tumor in situ. Fig. 6 G displays that DOX was extensively distributed in liver, spleen, kidney, heart, but the relatively weak fluorescence was found in tumor of DOX group. In contrast, less DOX was accumulated in liver, spleen, kidney, and heart in the M-MSNs-DOX group, while more DOX was in the tumor, especially in the magnetic field group. These results indicate that M-MSNs-DOX is magnet-directed to the tumor site and released in acidic tumor microenvironment, which results in the improved anticancer efficacy in the orthotropic liver tumor model.\nTo further confirm the therapeutic effect of M-MSNs-DOX, the\ntransplanted liver tumor model was replicated in nude mice by subcutaneous inoculation of 2 106 HepG2 cells. One week later, DOX (1 mg kg 1) andM-MSNs-DOX (5 mg kg 1, equal to containing 1 mg kg 1 DOX) were administrated by intravenous injection once every 3 days for another 25 days (Fig. 7A). Fig. 7B-E showed that tumor growth was completely inhibited in the DOX group with the lowest tumor volume and tumor final weight compared with the other group. Unfortunately, the body weight in the DOX group is also greatly reduced with dyscrasia symptoms. This indicates that DOX exerts excellent tumor inhibition (It, 85.3 ± 4.3%) in combination with reduced severe side effects. M-MSNs-DOX under external magnetic field displays a significantly higher rate of tumor inhibition (It, 50.2 ± 3.1%), compared to that of 24.7 ± 4.6% in theMMSNs-DOX group, suggesting magnetic field enhancement by about 25% of the inhibitory tumor efficacy. Noticeably, the body weights of M-MSNs-DOX with or without exposure to a magnetic field do not differ from the control group, and general status is good, suggesting that M-MSNs-DOX not only suppresses the tumor growth, but also reduces the adverse effect of DOX. Moreover, control group and M-MSNs-PEG show no difference in tumor volume, tumor final weight and body weight of mice. It is well known that magnetic targeting will enhanced EPR effect of magnetic theranostic agent specifically in the targeted tumor in vivo [46]. As expected, the better tumor accumulation of magnetic targeted group was correlated with a longer survival time and a longer regrowth delay compared to the passively-targeted group. Taken together, these two experiments both suggested the potency of MMSNs-DOX under magnetic excitation for targeted delivery of\nchemotherapeutics to liver cancers."
    }, {
      "heading" : "3.7. M-MSNs reduces the systemic toxicity of DOX",
      "text" : "To evaluate the systemic toxicity of the proposed nano-bullet MMSNs-DOX, the toxicological index including body weight, blood chemistry and histological examination of major organs were investigated by analyzing the aforementioned mice transplanted liver tumor model at the end of the experiment. Hepatic function enzymes including alanine transaminase (ALT), aspartate transaminase (AST) were observed to be significantly increased in mice treated with a dosage of molecular DOX compared to the control group (Fig. 8A and B). Enhanced activity was also observed for kidney function enzymes including blood urea nitrogen (BUN) and creatinine (CRE) (Fig. 8C and D), but significant reduction was observed, when the same DOX amount was delivered by M-MSNsDOX. On the contrary, there appeared significant reduction, when the same DOX amount was delivered by M-MSNs. Moreover, cardiotoxicity as an acknowledged adverse effect of dosage of molecular DOX was also observed here [47]. An elevated level of phosphocreatine kinase (CK) in the serum was observed in the molecular DOX dosage group. This adverse effect was totally minimized by the DOX-loaded M-MSNs (Fig. 8E). In addition, the organ weight indexes of livers and spleen in the DOX group are significant lower than that of the control (Fig. 8F), indicating the immune system was inhibited by DOX, while M-MSNs-DOX minimized the damage to immune organs.\nTo further investigate the influences of M-MSNs-DOX on the histopathology of the major organs, tissue slices were prepared from brain, heart, liver, spleen, lung and kidney of mice with different treatments at 25 days. Images of were taken at 40 magnification with standard haematoxylin and eosin staining (H&E). As shown in Fig. 9, pathological damages were not observed in the lung, kidney, liver or spleen. However, myocardium tissue swelling was seen in the DOX group, and cardiac myocytes lined up in order with clear structure in the other groups, which is consistent with the CK levels we detected at the same time. Consequently, we have demonstrated that M-MSNs-DOX reduced cardiovascular toxicity. Additionally the biodistribution of M-MSNs-DOX was examined based on the evaluation of Prussian blue staining in tumor and normal tissue sections. As shown in Fig. 10, M-MSNs-DOX appearing as blue dots accumulates in liver, spleen and tumor tissue, while it is not seen in kidney, heart and lung tissue, suggesting tail vein injection of M-MSNs-DOX leads to selective delivery of the nanoparticles into tumor tissues as well as nonspecific uptake by the Kupffer cells in the liver and macrophages in the spleen. More importantly, the magnetic field enhanced retention of M-MSNsDOX in the tumor site is more than M-MSNs-DOX group without magnetic field, indicating the efficiency of magnetic targeting of MMSNs-DOX, which is consistent with our DOX accumulation experiments (Fig. 6G). Note that past reports claimed that iron nanoparticles were degraded in the endosomes and lysosomes of macrophages. It is feasible to anticipate that M-MSNs-DOX in the liver and spleen can be degraded inside microphages."
    }, {
      "heading" : "4. Conclusions",
      "text" : "In summary, we attempted to compile multiple functional components into a Janus Fe3O4-mSiO2 as “nano-bullets”, which possessed well defined pore structures loading DOX, high tumor cell endocytosis, magnetic responsiveness, and low systemic toxicity. The novel nanodrug M-MSN-DOX selectively inhibited cancer cell growth especially in magnetic field environment, while showing weak influence on human normal cells in vitro. The transplanted tumor liver tumor model in nude mice demonstrated that the Janus nano-bullets greatly inhibited tumor growth and significantly reduced systemic toxicity. Our study shed light on a new targeting strategy in liver cancer treatment based on a novel Janus nanobullet to achieve the most efficient and safe liver cancer therapy."
    }, {
      "heading" : "Acknowledgements",
      "text" : "Prof. Bai Yang, Prof. Xiang-gui Kong, Dr. Fang-zhong Shen, Dr. Guang-fan Chi, Dr. Jing Bai, Dr. Mengmeng Lu, Dr. Ying-shuai Wang, Dr. Yun-lu Sun, Dr. Qiong-shu Li, Dr. Mingqiang Li, Dr. Mengmeng Lu, Xuan-ang Xiao, Xin Zhang, Wen-liang Liu and Hui-lin Zheng are acknowledged for their help in preparing the paper. This work is sponsored by National Natural Science Foundation of China (81071886, 81201804, 81371681), the Science and Technology Support Program of Jilin province (20090441, 201205006), the Science and Technology Department of Suzhou City (No. ZXY201434), the National Research Foundation for the Doctoral Program of Higher Education of China (20120061120079) and the Opening Project of State Key Laboratory of Supramolecular Structure and Materials of Jilin University under Grant No. SKLSSM 201504 and No.SKLSSM 201317, Most of experiments were carried out at Nanomedicine Engineering Laboratory of Jilin Province and Preclinical Pharmacology R&D Center of Jilin Province."
    }, {
      "heading" : "Appendix A. Supplementary data",
      "text" : "Supplementary data related to this article can be found at http:// dx.doi.org/10.1016/j.biomaterials.2016.05.030."
    } ],
    "references" : [ {
      "title" : "Hepatocellular carcinoma: clinical frontiers and perspectives",
      "author" : [ "J. Bruix", "G.J. Gores", "V. Mazzaferro" ],
      "venue" : "Gut 63 ",
      "citeRegEx" : "1",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Recent progress in understanding",
      "author" : [ "M. Maluccio", "A. Covey" ],
      "venue" : "diagnosing, and treating hepatocellular carcinoma, CA Cancer J. Clin. 62 ",
      "citeRegEx" : "2",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Hepatocellular carcinoma: a global view",
      "author" : [ "J.D. Yang", "L.R. Roberts" ],
      "venue" : "Nat. Rev. Gastroenterol. Hepatol. 7 ",
      "citeRegEx" : "3",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "Surveillance for early diagnosis of hepatocellular carcinoma: how best to do it? World J",
      "author" : [ "E.G. Giannini", "A. Cucchetti", "V. Erroi", "F. Garuti", "F. Odaldi", "F. Trevisani" ],
      "venue" : "Gastroenterol. 19 ",
      "citeRegEx" : "4",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Targeted therapies for hepatocellular carcinoma",
      "author" : [ "A. Villanueva", "J.M. Llovet" ],
      "venue" : "Gastroenterology 140 ",
      "citeRegEx" : "5",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebocontrolled trial, Lancet Oncol",
      "author" : [ "A.L. Cheng", "Y.K. Kang", "Z.D. Chen", "C.J. Tsao", "S.K. Qin", "J.S. Kim" ],
      "venue" : null,
      "citeRegEx" : "6",
      "shortCiteRegEx" : "6",
      "year" : 2009
    }, {
      "title" : "A",
      "author" : [ "R.G. Gish", "C. Porta", "L. Lazar", "P. Ruff", "R. Feld" ],
      "venue" : "Croitoru, et al., Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin, J. Clin. Oncol. 25 ",
      "citeRegEx" : "7",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "P",
      "author" : [ "C.N. Zhang", "W. Wang", "T. Liu", "Y.K. Wu", "H. Guo" ],
      "venue" : "Wang, et al., Doxorubicinloaded glycyrrhetinic acid-modified alginate nanoparticles for liver tumor chemotherapy, Biomaterials 33 ",
      "citeRegEx" : "8",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Z",
      "author" : [ "D. Shao", "J. Li", "Y. Pan", "X. Zhang", "X. Zheng" ],
      "venue" : "Wang, et al., Noninvasive theranostic imaging of HSV-TK/GCV suicide gene therapy in liver cancer by folatetargeted quantum dot-based liposomes, Biomater. Sci UK 3 ",
      "citeRegEx" : "9",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Nanomedicine in cancer therapy: challenges",
      "author" : [ "A. Wicki", "D. Witzigmann", "V. Balasubramanian", "J. Huwyler" ],
      "venue" : "opportunities, and clinical applications, J. Control Release 200 ",
      "citeRegEx" : "10",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "T",
      "author" : [ "H. Meng", "W.X. Mai", "H.Y. Zhang", "M. Xue" ],
      "venue" : "Xia, S.J. Lin, et al., Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast Cancer in vitro and in vivo, ACS Nano 7  ",
      "citeRegEx" : "11",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "S",
      "author" : [ "J.E. Chang", "W.S. Shim", "S.G. Yang", "E.Y. Kwak" ],
      "venue" : "Chong, D.D. Kim, et al., Liver Cancer targeting of doxorubicin with reduced distribution to the heart using hematoporphyrin-modified albumin nanoparticles in rats, Pharm. Res. 29 ",
      "citeRegEx" : "12",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "A magnetic mesoporous silica nanoparticle-based drug delivery system for photosensitive cooperative treatment of cancer with a mesopore-capping agent and mesopore-loaded drug",
      "author" : [ "N.Z. Knezevic", "V.S.Y. Lin" ],
      "venue" : "Nanoscale 5 ",
      "citeRegEx" : "13",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Multifunctional superparamagnetic iron oxide nanoparticles: design",
      "author" : [ "L. Zhang", "W.F. Dong", "H.B. Sun" ],
      "venue" : "synthesis and biomedical photonic applications, Nanoscale 5 ",
      "citeRegEx" : "14",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "F",
      "author" : [ "M. Ma", "H.R. Chen", "Y. Chen", "X. Wang" ],
      "venue" : "Chen, X.Z. Cui, et al., Au capped magnetic core/mesoporous silica shell nanoparticles for combined photothermo-/chemo-therapy and multimodal imaging, Biomaterials 33 ",
      "citeRegEx" : "15",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "F",
      "author" : [ "Y. Chen", "H.R. Chen", "S.J. Zhang" ],
      "venue" : "Chen, L.X. Zhang, J.M. Zhang, et al., Multifunctional mesoporous nanoellipsoids for biological bimodal imaging and magnetically targeted delivery of anticancer drugs, Adv. Funct. Mater. 21 ",
      "citeRegEx" : "16",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Magnetic hollow spheres of periodic mesoporous organosilica and Fe3O4 nanocrystals: fabrication and structure control",
      "author" : [ "L. Zhang", "S.Z. Qiao", "Y.G. Jin", "Z.G. Chen", "H.C. Gu", "G.Q. Lu" ],
      "venue" : "Adv. Mater. 20 ",
      "citeRegEx" : "17",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "Extension of the stober method to construct mesoporous SiO2 and TiO2 shells for uniform multifunctional core-shell structures",
      "author" : [ "W. Li", "D.Y. Zhao" ],
      "venue" : "Adv. Mater. 25 ",
      "citeRegEx" : "18",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Biphasic Janus particles with nanoscale anisotropy",
      "author" : [ "K.H. Roh", "D.C. Martin", "J. Lahann" ],
      "venue" : "Nat. Mater. 4 ",
      "citeRegEx" : "19",
      "shortCiteRegEx" : null,
      "year" : 2005
    }, {
      "title" : "Particles adsorbed at the oil-water interface: a theoretical comparison between spheres of uniform wettability and “Janus” particles",
      "author" : [ "B. Binks", "P. Fletcher" ],
      "venue" : "Langmuir 17 ",
      "citeRegEx" : "20",
      "shortCiteRegEx" : null,
      "year" : 2001
    }, {
      "title" : "Janus particles: synthesis",
      "author" : [ "A. Walther", "A.H. Muller" ],
      "venue" : "self-assembly, physical properties, and applications, Chem. Rev. 113 ",
      "citeRegEx" : "21",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Fabrication",
      "author" : [ "J. Hu", "S. Zhou", "Y. Sun", "X. Fang", "L. Wu" ],
      "venue" : "properties and applications of Janus particles, Chem. Soc. Rev. 41 ",
      "citeRegEx" : "22",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Janus nanoparticles: materials",
      "author" : [ "L.T. Tran", "S. Lesieur", "V. Faivre" ],
      "venue" : "preparation and recent advances in drug delivery, Expert Opin. Drug Deliv. 11 ",
      "citeRegEx" : "23",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Anisotropic particles with patchy",
      "author" : [ "J.Z. Du", "R.K. O'Reilly" ],
      "venue" : "multicompartment and Janus architectures: preparation and application, Chem. Soc. Rev. 40 ",
      "citeRegEx" : "24",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Templated synthesis of amphiphilic nanoparticles at the liquid-liquid interface",
      "author" : [ "D.M. Andala", "S.H. Shin", "H.Y. Lee", "K.J. Bishop" ],
      "venue" : "ACS Nano 6 ",
      "citeRegEx" : "25",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Synthesis and characterization of Janus gold nanoparticles",
      "author" : [ "H. Kim", "R.P. Carney", "J. Reguera", "Q.K. Ong", "X. Liu", "F. Stellacci" ],
      "venue" : "Adv. Mater. 24 ",
      "citeRegEx" : "26",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Synthesis",
      "author" : [ "M. Lattuada", "T.A. Hatton" ],
      "venue" : "properties and applications of Janus nanoparticles, Nano Today 6 ",
      "citeRegEx" : "27",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Janus nanoparticles: materials",
      "author" : [ "L.T.C. Tran", "S. Lesieur", "V. Faivre" ],
      "venue" : "preparation and recent advances in drug delivery, Expert Opin. Drug Deliv. 11 ",
      "citeRegEx" : "28",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Magnetic-mesoporous Janus nanoparticles",
      "author" : [ "L. Zhang", "F. Zhang", "W.F. Dong", "J.F. Song", "Q.S. Huo", "H.B. Sun" ],
      "venue" : "Chem. Commun. 47 ",
      "citeRegEx" : "29",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "F",
      "author" : [ "C. Lu", "X.J. Liu", "Y.F. Li" ],
      "venue" : "Yu, L.H. Tang, Y.J. Hu, et al., Multifunctional Janus hematite silica nanoparticles: mimicking peroxidase-like activity and sensitive colorimetric detection of glucose, ACS Appl. Mater. Interfaces 7 ",
      "citeRegEx" : "30",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Multifunctional superparamagnetic Janus particles",
      "author" : [ "K.P. Yuet", "D.K. Hwang", "R. Haghgooie", "P.S. Doyle" ],
      "venue" : "Langmuir 26 ",
      "citeRegEx" : "31",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "L",
      "author" : [ "H. Xia", "L. Zhang", "Q.D. Chen" ],
      "venue" : "Guo, H.H. Fang, X.B. Li, et al., Band-gapcontrollable photonic crystals consisting of magnetic nanocrystal clusters in a solidified polymer matrix, J. Phys. Chem. C 113 ",
      "citeRegEx" : "32",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "Surface functionalization of magnetic mesoporous silica nanoparticles for controlled drug release",
      "author" : [ "B.S. Chang", "J. Guo", "C.Y. Liu", "J. Qian", "W.L. Yang" ],
      "venue" : "J. Mater. Chem. 20 ",
      "citeRegEx" : "33",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "X",
      "author" : [ "D. Shao", "Z. Wang", "W.F. Dong", "X. Zhang" ],
      "venue" : "Zheng, X.A. Xiao, et al., Facile synthesis of core-shell magnetic mesoporous silica nanoparticles for pH-sensitive anticancer drug delivery, Chem. Biol. Drug Des. 86 ",
      "citeRegEx" : "34",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Evaluation of quantum dot cytotoxicity based on intracellular uptake",
      "author" : [ "E. Chang", "N. Thekkek", "W.W. Yu", "V.L. Colvin", "R. Drezek" ],
      "venue" : "Small 2 ",
      "citeRegEx" : "35",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "M",
      "author" : [ "D. Shao", "J. Li", "F.Y. Guan", "Y. Pan", "X.N. Xiao" ],
      "venue" : "Zhang, et al., Selective inhibition of liver cancer growth realized by the intrinsic toxicity of a quantum dot-lipid complex, Int. J. Nanomed. 9 ",
      "citeRegEx" : "36",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Endocytosis and intracellular transport of nanoparticles: present knowledge and need for future studies",
      "author" : [ "T.G. Iversen", "T. Skotland", "K. Sandvig" ],
      "venue" : "Nano Today 6 ",
      "citeRegEx" : "37",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review",
      "author" : [ "H. Maeda", "J. Wu", "T. Sawa", "Y. Matsumura", "K. Hori" ],
      "venue" : "J. Control Release 65 ",
      "citeRegEx" : "38",
      "shortCiteRegEx" : null,
      "year" : 2000
    }, {
      "title" : "The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake",
      "author" : [ "H. Maeda", "H. Nakamura", "J. Fang" ],
      "venue" : "lowering of systemic toxicity, and distinct tumor imaging in vivo, Adv. Drug Deliv. Rev. 65 ",
      "citeRegEx" : "39",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Nanoscale theranostics for physical stimulusresponsive cancer therapies",
      "author" : [ "Q. Chen", "H.T. Ke", "Z.F. Dai", "Z. Liu" ],
      "venue" : "Biomaterials 73 (2015) 214e230.  D. Shao et al. / Biomaterials 100 ",
      "citeRegEx" : "40",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "I",
      "author" : [ "G. Mikhaylov", "U. Mikac", "A.A. Magaeva", "V.I. Itin", "E.P. Naiden" ],
      "venue" : "Psakhye, et al., Ferri-liposomes as an MRI-visible drug-delivery system for targeting tumours and their microenvironment, Nat. Nanotechnol. 6 ",
      "citeRegEx" : "41",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Magnetic targeting enhanced theranostic strategy based on multimodal imaging for selective ablation of cancer",
      "author" : [ "Z. Li", "S. Yin", "L. Cheng", "K. Yang", "Y. Li", "Z. Liu" ],
      "venue" : "Adv. Funct. Mater. 24 ",
      "citeRegEx" : "42",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Magnetic field enhanced cell uptake efficiency of magnetic silica mesoporous nanoparticles",
      "author" : [ "Q. Liu", "J.X. Zhang", "W.L. Xia", "H.C. Gu" ],
      "venue" : "Nanoscale 4 ",
      "citeRegEx" : "43",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Oral administration of antidoxorubicin monoclonal antibody prevents chemotherapy-induced  gastrointestinal toxicity in mice",
      "author" : [ "D. Morelli", "S. Menard", "M.I. Colnaghi", "A. Balsari" ],
      "venue" : "Cancer Res. 56 ",
      "citeRegEx" : "44",
      "shortCiteRegEx" : null,
      "year" : 1996
    }, {
      "title" : "E",
      "author" : [ "H. Urakawa", "S. Tsukushi", "H. Sugiura", "K. Yamada", "Y. Yamada" ],
      "venue" : "Kozawa, et al., Neoadjuvant and adjuvant chemotherapy with doxorubicin and ifosfamide for bone sarcomas in adult and older patients, Oncol. Lett. 8 ",
      "citeRegEx" : "45",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Y",
      "author" : [ "C. Wang", "X. Sun", "L. Cheng", "S. Yin", "G. Yang" ],
      "venue" : "Li, et al., Multifunctional theranostic red blood cells for magnetic-field-enhanced in vivo combination therapy of cancer, Adv. Mater. 26 ",
      "citeRegEx" : "46",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Doxorubicin-induced cardiomyopathy: from the cardiotoxic mechanisms to management",
      "author" : [ "G. Takemura", "H. Fujiwara" ],
      "venue" : "Cardiovasc. Dis. 49 ",
      "citeRegEx" : "47",
      "shortCiteRegEx" : null,
      "year" : 2007
    } ],
    "referenceMentions" : [ {
      "referenceID" : 3,
      "context" : "The ensuing researches pertaining to liver cancer provided implication of the importance of early diagnosis and targeting chemotherapy in circumventing the high mortality of liver cancer [4,5].",
      "startOffset" : 187,
      "endOffset" : 192
    }, {
      "referenceID" : 4,
      "context" : "The ensuing researches pertaining to liver cancer provided implication of the importance of early diagnosis and targeting chemotherapy in circumventing the high mortality of liver cancer [4,5].",
      "startOffset" : 187,
      "endOffset" : 192
    }, {
      "referenceID" : 5,
      "context" : "cn chemotherapeutic drugs is prescribed as a routine in clinical treatment of advanced liver cancer, nevertheless concomitantly eliciting severe adverse effects due to non-specific cytotoxicity [6,7].",
      "startOffset" : 194,
      "endOffset" : 199
    }, {
      "referenceID" : 6,
      "context" : "cn chemotherapeutic drugs is prescribed as a routine in clinical treatment of advanced liver cancer, nevertheless concomitantly eliciting severe adverse effects due to non-specific cytotoxicity [6,7].",
      "startOffset" : 194,
      "endOffset" : 199
    }, {
      "referenceID" : 10,
      "context" : "In consequence, tumor-targeted delivery or tumor cell-targeted cytotoxicity by virtue of multifunctionalities of drug delivery systems can elicit appreciable drug availability, thus improved therapeutic efficacy to the tumors and reduced non-specific toxicity for vital functional organs [11,12].",
      "startOffset" : 288,
      "endOffset" : 295
    }, {
      "referenceID" : 11,
      "context" : "In consequence, tumor-targeted delivery or tumor cell-targeted cytotoxicity by virtue of multifunctionalities of drug delivery systems can elicit appreciable drug availability, thus improved therapeutic efficacy to the tumors and reduced non-specific toxicity for vital functional organs [11,12].",
      "startOffset" : 288,
      "endOffset" : 295
    }, {
      "referenceID" : 16,
      "context" : "However, several drawbacks are connected with the core-shell architecture, including considerable interference in magnetic response, and limited presence of mesopore formation constrained their clinical applications [17,18].",
      "startOffset" : 216,
      "endOffset" : 223
    }, {
      "referenceID" : 17,
      "context" : "However, several drawbacks are connected with the core-shell architecture, including considerable interference in magnetic response, and limited presence of mesopore formation constrained their clinical applications [17,18].",
      "startOffset" : 216,
      "endOffset" : 223
    }, {
      "referenceID" : 18,
      "context" : "Janus particles, defined by Casagrande and de Gennes after the double-faced Roman mythology god, have emerged as a new division of colloidal structures [19,20].",
      "startOffset" : 152,
      "endOffset" : 159
    }, {
      "referenceID" : 19,
      "context" : "Janus particles, defined by Casagrande and de Gennes after the double-faced Roman mythology god, have emerged as a new division of colloidal structures [19,20].",
      "startOffset" : 152,
      "endOffset" : 159
    }, {
      "referenceID" : 24,
      "context" : "with other isotopic nanoparticles [25,26].",
      "startOffset" : 34,
      "endOffset" : 41
    }, {
      "referenceID" : 25,
      "context" : "with other isotopic nanoparticles [25,26].",
      "startOffset" : 34,
      "endOffset" : 41
    }, {
      "referenceID" : 26,
      "context" : "non-invasive imaging, and/or therapeutic applications [27,28].",
      "startOffset" : 54,
      "endOffset" : 61
    }, {
      "referenceID" : 27,
      "context" : "non-invasive imaging, and/or therapeutic applications [27,28].",
      "startOffset" : 54,
      "endOffset" : 61
    }, {
      "referenceID" : 28,
      "context" : "Uniform sized M-MSNs were synthesized using the previously reported method [29].",
      "startOffset" : 75,
      "endOffset" : 79
    }, {
      "referenceID" : 31,
      "context" : "The Fe3O4 magnetic spheres were produced using a high temperature hydrolysis reaction [32].",
      "startOffset" : 86,
      "endOffset" : 90
    }, {
      "referenceID" : 32,
      "context" : "M-MSNswere functionalizedwitheNH2 using the post-grafting method [33].",
      "startOffset" : 65,
      "endOffset" : 69
    }, {
      "referenceID" : 34,
      "context" : "The left hepatic lobe was gently extruded, and then slowly inserted about 1 mm3 H22 tumor tissue from H22 tumor-bearing model as above-mentioned [35].",
      "startOffset" : 145,
      "endOffset" : 149
    }, {
      "referenceID" : 8,
      "context" : "The mice HepG2 xenograft model was replicated as abovementioned [9].",
      "startOffset" : 64,
      "endOffset" : 67
    }, {
      "referenceID" : 31,
      "context" : "Firstly, water-dispersible Fe3O4 cores with a diameter of approximately 100 nm were prepared via a high temperature hydrolysis reaction using polyacrylic acid as a stabilizer [32].",
      "startOffset" : 175,
      "endOffset" : 179
    }, {
      "referenceID" : 32,
      "context" : "Aiming for pH-responsive DOX release, MMSNs were functionalized with eCOOH using the post-grafting method [33].",
      "startOffset" : 106,
      "endOffset" : 110
    }, {
      "referenceID" : 33,
      "context" : "It is worthwhile to note that the saturation magnetization of Janus M-MSNs was much higher than our previously reported core-shell M-MSNs (41 emu g 1) [34].",
      "startOffset" : 151,
      "endOffset" : 155
    }, {
      "referenceID" : 34,
      "context" : "To explore the potential utility of the proposed formulation as drug delivery vehicle, it is critical to determine its cellular uptake activity, particularly, the cellular uptake efficiency to tumor cells as compared to healthy cells [35].",
      "startOffset" : 234,
      "endOffset" : 238
    }, {
      "referenceID" : 35,
      "context" : "Apparently, preferable internalization into the tumor cells over healthy cells would elicit selective therapeutic efficacy to the tumors and reduce the adverse toxicity [36].",
      "startOffset" : 169,
      "endOffset" : 173
    }, {
      "referenceID" : 37,
      "context" : "Nanoparticulates were verified to be capable of passive accumulation into the tumors through the enhanced permeability and retention (EPR) effect [38,39].",
      "startOffset" : 146,
      "endOffset" : 153
    }, {
      "referenceID" : 38,
      "context" : "Nanoparticulates were verified to be capable of passive accumulation into the tumors through the enhanced permeability and retention (EPR) effect [38,39].",
      "startOffset" : 146,
      "endOffset" : 153
    }, {
      "referenceID" : 39,
      "context" : "Recent studies claimed that this passive tumor accumulation could be facilitated by an external stimulus, such as magnetic field (MF), light, and ultra-sound [40,41].",
      "startOffset" : 158,
      "endOffset" : 165
    }, {
      "referenceID" : 40,
      "context" : "Recent studies claimed that this passive tumor accumulation could be facilitated by an external stimulus, such as magnetic field (MF), light, and ultra-sound [40,41].",
      "startOffset" : 158,
      "endOffset" : 165
    }, {
      "referenceID" : 41,
      "context" : "As one intriguing approach, magnetic-mediated targeting via an external magnetic field on the tumor site was able to direct transportation of magnetic nanoparticles to the tumor sites [42,43].",
      "startOffset" : 184,
      "endOffset" : 191
    }, {
      "referenceID" : 42,
      "context" : "As one intriguing approach, magnetic-mediated targeting via an external magnetic field on the tumor site was able to direct transportation of magnetic nanoparticles to the tumor sites [42,43].",
      "startOffset" : 184,
      "endOffset" : 191
    }, {
      "referenceID" : 43,
      "context" : "But its application in clinic is restricted due to its severe non-specific side-effects such as dosedependent cardiotoxicity [44,45].",
      "startOffset" : 125,
      "endOffset" : 132
    }, {
      "referenceID" : 44,
      "context" : "But its application in clinic is restricted due to its severe non-specific side-effects such as dosedependent cardiotoxicity [44,45].",
      "startOffset" : 125,
      "endOffset" : 132
    }, {
      "referenceID" : 33,
      "context" : "determined by UVevis spectrophotometry, which is much higher than the 49% of loading efficiency in core-shell M-MSNs [34].",
      "startOffset" : 117,
      "endOffset" : 121
    }, {
      "referenceID" : 45,
      "context" : "It is well known that magnetic targeting will enhanced EPR effect of magnetic theranostic agent specifically in the targeted tumor in vivo [46].",
      "startOffset" : 139,
      "endOffset" : 143
    }, {
      "referenceID" : 46,
      "context" : "Moreover, cardiotoxicity as an acknowledged adverse effect of dosage of molecular DOX was also observed here [47].",
      "startOffset" : 109,
      "endOffset" : 113
    } ],
    "year" : 2016,
    "abstractText" : "Tumor-targeted delivery of anti-cancer drugs with controlled drug release function has been recognized as a promising strategy for pursuit of increased chemotherapeutic efficacy and reduced adverse effects. Development of magnetic nanoparticulates as delivery carriers to accommodate cytotoxic drugs for liver cancer treatment has evoked immense interest with respect to their convenience in biomedical application. Herein, we engineered multifunctional Janus nanocomposites, characterized by a head of magnetic Fe3O4 and a body of mesoporous SiO2 containing doxorubicin (DOX) as “nano-bullets” (M-MSNsDOX). This nanodrug formulation possessed nanosize with controlled aspect-ratio, defined abundance in pore structures, and superior magnetic properties. M-MSN-DOX was determined to induce selective growth inhibition to the cancer cell under magnetic field rather than human normal cells due to its preferable endocytosis by the tumor cells and pH-promoted DOX release in the interior of cancer cells. Ultimately, both subcutaneous and orthotropic liver tumor models in mice have demonstrated that the proposed Janus nano-bullets imposed remarkable suppression of the tumor growth and significantly reduced systematic toxicity. Taken together, this study demonstrates an intriguing targeting strategy for liver cancer treatment based on a novel Janus nano-bullet, aiming for utilization of nanotechnology to obtain safe and efficient treatment of liver cancer. © 2016 Elsevier Ltd. All rights reserved.",
    "creator" : "Elsevier"
  }
}